Capital Royalty launches $805M fund for biotech, healthcare deals

Houston-based Capital Royalty has pieced together an $805 million fund to back a new package of loans and royalty deals with biotechs, pharma and other healthcare companies looking for some "alternative" sources of financing. Founded by former Hicks, Muse, Tate & Furst partner Charles Tate 10 years ago, fund managers plan to look for investments ranging from $20 million to $200 million. "The high level of investor demand for this fund reflects Capital Royalty's consistent performance and differentiated investment strategy," said Tate in a statement. Release

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.